Clinical trial
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or…
NCT00354913 · Duke University, Other · Completed
Key facts
| NCT number | NCT00354913 |
|---|---|
| Title | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma |
| Official title | A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma, Gliosarcoma |
| Intervention type | Drug |
| Interventions | hydroxyurea, imatinib mesylate |
| Enrollment | 21 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Oct 1, 2010 |
| First posted | Jul 20, 2006 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: